Inflammatory Breast Carcinoma Clinical Trial
Official title:
Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
Verified date | December 2019 |
Source | Dana-Farber Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This research study is a pilot study, which tests the ability of an investigational compound
to be used in humans for further studies. "Investigational" means that 89Zr-bevacizumab for
PET/CT imaging is being studied. It also means that the FDA (U.S. Food and Drug
Administration) has not approved 89Zr-bevacizumab for PET/CT imaging for use in patients,
including people with your type of cancer.
89Zr-bevacizumab is a newly developed radiotracer. Radiotracers are compounds or drugs that
are attached to small amounts of a radioactive substance. The amount of the compound or drug
in a radiotracer is also very small. Radiotracers are used to make images of processes that
are happening in the body, but they do not affect how the body works. 89Zr-bevacizumab is
made up of the drug bevacizumab and the radioactive substance zirconium-89 (89Zr).
89Zr-bevacizumab is used for an imaging procedure called positron emission
tomography/computed tomography (PET/CT). This radiotracer has been used in other research
studies. Information from those other research studies suggests that 89Zr-bevacizumab-PET/CT
imaging may be able to measure new blood vessel formation to determine where the cancer is in
your body and if your cancer is being killed by chemotherapy.
Status | Completed |
Enrollment | 2 |
Est. completion date | March 17, 2017 |
Est. primary completion date | March 17, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: Participants must meet the following criteria on screening examination to be eligible to participate in the study: - Participants must have histologically or cytologically confirmed HER2 negative invasive breast adenocarcinoma. - Participants must have clinical characteristics consistent with IBC, characterized by a rapid onset of clinical findings exemplified as diffuse edema and erythema of the breast, often without a palpable mass. - Age = 21 years. Because no dosing or adverse event data are currently available on the use of 89Zr-bevacizumab in participants <21 years of age, children are excluded from this study but will be eligible for future pediatric trials. - Any stage is eligible. - Participants must be eligible for preoperative chemotherapy for IBC as determined by the treating physician. - The effects of 89Zr-bevacizumab on the developing human fetus are unknown. For this reason and because radiopharmaceuticals may be teratogenic, women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. - Ability and willingness to comply with the study procedures. - Ability to understand and the willingness to sign a written informed consent document. - Participants must be willing to have research biopsies at baseline and after 2 cycles of preoperative chemotherapy, and possibly at the completion of preoperative chemotherapy. - ECOG performance status = 2. Exclusion Criteria: - Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study: - Pregnant women are excluded from this study because 89Zr-bevacizumab and 18F-FDG are radiopharmaceuticals with the potential for teratogenic effects. Because of the radiation exposure to a nursing infant from 89Zr-bevacizumab and 18F-FDG, women who are breastfeeding are also excluded from this study. In addition, bevacizumab may cause fetal harm based on animal studies (2). - Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Major surgery or significant bleeding episodes within 28 days before study initiation. Major surgery does not include: breast or other biopsies obtained for diagnosis, placement of radio-opaque clip to localize a tumor or tumors for subsequent surgical resection, placement of central venous access, pretreatment lymph node sampling. Significant bleeding episodes are defined for the purpose of this study as hemoptysis or upper/lower gastrointestinal bleeding. Although bevacizumab will be administered in tracer quantities in this study and is not expected to have pharmacologic effects, participants with major surgery or significant bleeding episodes within 28 days before study initiation may be at a higher risk of bleeding. Contraindications for MRI with contrast or PET/CT including: - Cardiac pacemaker, implanted cardiac defibrillator, pacing wires, internal electrodes - Aneurysm clips - Cochlear, otologic, or other ear implant - Tissue expander - Swan-Ganz or Thermo Dilution - Moderate renal insufficiency (estimated GFR less than 60 mL/min/1.73 m2) to end stage renal disease (estimated GFR less than 15 mL/min/1.73 m2 or a serum creatinine more than 3 mg/dL), who are not on dialysis, and patients with renal failure on chronic dialysis - Severe claustrophobia - History of multiple or severe allergic reactions attributed to immunoglobulins or MRI contrast agents. - Any past or current condition that in the opinion of the study investigators would confound the results of the study or pose additional risk to the patient by their participation in the study. |
Country | Name | City | State |
---|---|---|---|
United States | Brigham and Womens Hospital | Boston | Massachusetts |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Dana-Farber Cancer Institute | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Visualization of primary IBC tumor and visualization and number of distant metastases | This is an exploratory outcome measure to see if 89Zr-bevacizumab detects primary and metastatic IBC tumor in a similar fashion | 2 years | |
Other | Percent change in 89Zr-bevacizumab tumor uptake in primary IBC tumor between the baseline and post preoperative chemotherapy PET/CT scans and residual cancer burden at mastectomy/tissue sampling if residual disease | This outcome measure is exploratory to investigate whether changes in tumor uptake of 89Zr-bevacizumab can predict response in mastectomy specimens. | 2 years | |
Primary | Quality Control Standards for Radiopharmamceuticals and Number of Successfully Acquired 89Zr-bevacizumab-PET/CT scans | In order to determine if 89Zr-bevacizumab-PET/CT scanning is feasible, we will determine results of radiolabeling of chelated bevacizumab including the radiolabeling yield, specific activity, and radiochemical purity and the number of successfully acquired 89Zr-bevacizumab-PET/CT scans. | 2 years | |
Secondary | Number of related adverse events after the intravenous administration of 89Zr-bevacizumab. | To determine the safety of 89Zr-bevacizumab-PET/CT imaging in patients with IBC, the number of adverse events related to the radiotracer (89Zr-bevacizumab) will be determined. | 2 years | |
Secondary | Biodistribution of 89Zr-bevacizumab and individual organ and effective dose of 89Zr-bevacizumab | 2 Years | ||
Secondary | Amount of 89Zr-bevacizumab uptake in IBC tumor and measures of tumor angiogenesis in research biopsy specimens. | The amount of 89Zr-bevacizumab uptake in IBC tumor will be primarily given by standardized uptake values from PET/CT imaging. Measures of tumor angiogenesis are intratumoral microvessel density (MVD), vessel diameter, and vascular pericyte coverage | 2 Years | |
Secondary | Changes in tumor uptake of 89Zr-bevacizumab and FDG during and after preoperative chemotherapy and response in primary IBC tumor MRI. | This outcome aims to determine if 89Zr-bevacizumab provides similar results in regards to monitoring therapy response compared to standard modalities, FDG-PET/CT and MRI breast | 2 Years | |
Secondary | To correlate the changes in tumor uptake on 89Zr-bevacizumab-PET/CT with standard imaging response using MRI and FDG-PET/CT | 2 Years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00070252 -
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02876107 -
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
|
Phase 2 | |
Completed |
NCT02227082 -
Olaparib and Radiotherapy in Inoperable Breast Cancer
|
Phase 1 | |
Terminated |
NCT01755130 -
Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast Cancer
|
N/A | |
Recruiting |
NCT01641406 -
"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
|
Phase 2 | |
Active, not recruiting |
NCT01038258 -
Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy
|
N/A | |
Active, not recruiting |
NCT01730833 -
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
|
Phase 2 | |
Completed |
NCT03872388 -
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
|
Phase 2 | |
Recruiting |
NCT00477100 -
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
|